Cell Genesys GVAX Prostate Cancer Vaccine To Start Phase III Second-Quarter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cell Genesys’ GVAX prostate cancer vaccine is scheduled to enter Phase III at the end of the second quarter under FDA’s special protocol assessment program.